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Abstract
Background: The prevalence of gestational diabetes mellitus (GDM) is rising rapidly in many low- and middle-income
countries (LMICs). Most women with GDM in LMICs are undiagnosed and/or inadequately managed due to a lack of
knowledge and skills about GDM on the part of both providers and patients. Following contextual analysis, we developed
an educational/behavioural intervention for GDM delivered through a package of culturally tailored films. This trial aims to
evaluate whether the intervention can improve the timely detection and management of GDM in two LMIC settings.
Methods: Two independent cluster randomised controlled trials, one each to be conducted in Uganda and India. Thirty
maternity facilities in each country have been recruited to the study and randomised in a 1:1 ratio to the intervention and
control arms. The intervention comprises of three interconnected sets of films with the following aims: to improve
knowledge of GDM guidelines and skills of health providers, to raise awareness of GDM screening among pregnant
women and their families, and to improve confidence and skills in self-management among those diagnosed with GDM.
In facilities randomised to the intervention arm, a GDM awareness-raising film will be shown in antenatal care waiting
rooms, and four films for pregnant women with GDM will be shown in group settings and made available for viewing on
mobile devices. Short films for doctors and nurses will be presented at professional development meetings. Data will be
collected on approximately 10,000 pregnant women receiving care at participating facilities, with follow-up at 32 weeks
gestational age and 6 weeks postnatally. Women who self-report a GDM diagnosis will be invited for a clinic visit at 34
weeks. Primary outcomes are (a) the proportion of women who report a GDM diagnosis by 32 weeks of pregnancy and
(b) glycaemic control (fasting glucose and HbA1C) in women with GDM at ~34 weeks of pregnancy. The secondary
outcome is a composite measure of GDM-related adverse perinatal-neonatal outcome.
Discussion: Screening and management of GDM are suboptimal in most LMICs. We hypothesise that a scalable film-
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based intervention has the potential to improve the timely detection and management of GDM in varied LMIC settings.
Trial registration: ClinicalTrials.gov NCT03937050, registered on 3 May 2019. Clinical Trials Registry India CTRI/2020/02/
023605, registered on 26 February 2020.
Keywords: Gestational diabetes, Cluster randomised controlled trial, India, Uganda
Background
Gestational diabetes mellitus (GDM) is associated with
adverse perinatal outcomes and mortality [1–4]. Women
with GDM have a ~50% greater risk of developing type
2 diabetes mellitus later in life, and the risk of obesity
and diabetes among their offspring may also be in-
creased [5, 6]. The prevalence of GDM is rising rapidly
in many low and middle-income countries (LMICs),
mirroring the rising prevalence of obesity and diabetes.
In India, the age-standardised prevalence of GDM is es-
timated to be 28%, compared to 14% for high-income
countries [7]. Population-based data for sub-Saharan Af-
rica are sparse [8], but two recent hospital surveys from
Uganda reported GDM prevalence estimates of 16% and
32%, respectively [9, 10]. The considerable healthcare
utilisation costs of subsequent diabetes and premature
cardiovascular disease in mother and offspring—and
their impact on economic productivity—threatens the
development agenda of LMICs [11].
Experience from high-income countries suggests that
prevention of GDM, while desirable, is extremely chal-
lenging and resource-consuming [12, 13]. Timely detec-
tion and management of GDM may be a more cost-
effective and feasible goal for resource-constrained set-
tings and has been recommended as an early target for
policy makers in LMICs [4, 14]. Despite this, most
women with GDM in LMICs are undiagnosed and/or in-
adequately managed. A survey of key informants from
40 LMICs identified the unavailability of relevant guide-
lines and lack of knowledge about GDM on the part of
both providers and patients as a significant barrier to de-
tection and management of GDM [15, 16]. Limited
availability and access to follow-up care, and low motiv-
ation and compliance of the patients, often linked to a
lack of social support, were the other main factors iden-
tified. Where evidence-based GDM guidelines exist, they
are often poorly applied in practice. In a national survey
of doctors in India, which included specialist diabetolog-
ists and obstetricians, only a third were following the na-
tional guidelines for screening, of which two thirds
could not recall the protocol correctly [17]. In another
study conducted in Bangalore, India, only 50% of the
doctors demonstrated good knowledge of GDM man-
agement [18].
Educational interventions aimed at improving know-
ledge of clinical guidelines have been shown to be
effective in improving the practice of health providers
and clinical outcomes, including diabetes [19, 20].
Women with GDM are more motivated to manage their
condition due to its potential impact on the health of
the fetus, yet structured programmes tailored for women
with GDM are limited, even in high-income countries
[21]. Evidence suggests that even highly effective inter-
ventions often fail to scale up in LMICs, if they are logis-
tically challenging or require resources. Interventions
designed to address chronic diseases in LMIC need to
take into account specific structural and contextual fac-
tors which may influence efficacy and sustainability.
Film-based interventions are easily scalable and adapt-
able, they can help to transcend literacy barriers and can
be implemented with minimal infrastructure support.
However, there is a paucity of evidence regarding the ef-
fective use of film in health behavioural interventions in
LMIC settings [22].
We hypothesised that an educational/behavioural film-
based intervention targeting knowledge, skills and be-
haviours at multiple levels—health providers, and preg-
nant women and their families—could improve
detection and management of GDM in the short-term,
and over a period of time could also impact on systemic
barriers by increasing demand for better services, both
within the public and growing private healthcare sectors
in these countries (Fig. 1).
Methods
Aim
The primary aim of the two trials is to determine
whether an educational/behavioural intervention deliv-
ered through a package of culturally tailored films for
pregnant women, their family members and health pro-
viders can improve timely detection, glycaemic control
and clinical outcomes of women with GDM.
Design and setting
Two independent cluster-randomised controlled trials
will be conducted, one in Uganda (Wakiso, Mpigi and
Masaka) and one in India (Bengaluru). In Uganda,
Wakiso, Mpigi and Masaka districts are a mix of urban/
peri-urban areas and have relatively poor healthcare infra-
structure and lower antenatal care attendance. Bengaluru,
India is a densely populated urban area, with a relatively
good infrastructure, and high antenatal care attendance.
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In India, current national guidelines recommend universal
GDM screening using a single non-fasting glucose chal-
lenge test, with management following a structured path-
way of a diet and activity programme followed by medical
management where appropriate [23]. In Uganda, although
summary recommendations regarding GDM screening
and management are available [24], anecdotal evidence
suggests that screening is largely non-existent and treat-
ment is highly variable. As the two sites are at different
stages of economic transition and have differing existing
practise with regard to GDM screening and management,
they will provide important complementary information
about the generalizability of findings to other parts of sub-
Saharan Africa and India.
Participating health facilities
Government-funded health facilities providing maternity
care and recording at least 200 deliveries a year were re-
cruited as study sites. In Uganda, administrative clear-
ance was sought from all participating facilities and
District Health Offices. A total of 52 health facilities
were assessed for participation. In India, consent was ob-
tained from the Chief Health Officer (Clinical & Public
Health) of the Bruhat Bengaluru Mahanagara Palike
(Bengaluru, Karnataka), and 40 primary and secondary
level health facilities were visited. Thirty facilities in each
country were recruited to the trial, with an additional
two facilities in Uganda providing participants for quali-
tative intervention development work. A list of partici-
pating facilities is available from the authors.
Randomisation
Thirty health facilities in each country have been rando-
mised in a 1:1 ratio to receive the intervention or con-
trol, with randomisation conducted separately for each
country. Covariate constrained randomisation was per-
formed by a statistician using the cvcrand command in
Stata. Randomisation in India was restricted to ensure a
good balance between the randomised arms with respect
to the health facility (HF) level (levels I, II and III) and
facility size (number of deliveries per year). For Uganda,
the randomisation was restricted to ensure good balance
with respect to HF level (level IV versus level III), facility
and setting (rural versus non-rural).
Participant recruitment
Consent to randomisation has been obtained at the clus-
ter (health facility) level; individual-level informed con-
sent will be sought for study procedures including data
collection and blood tests. We plan to collect data on
Fig. 1 Hypothesised impact on barriers to GDM screening and management
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~10,000 pregnant women in each trial. All pregnant
women aged at least 18 years old and first attending for
antenatal care <32 weeks at a participating health facility
will be invited to participate in data collection. First
antenatal contact ≥32 weeks will constitute an exclusion
criterion as this is beyond the optimal gestational age for
GDM screening. Local fieldworkers will visit clinics and
screen women for eligibility. Consent to enter the study
will be sought only after a full explanation has been
given, an information leaflet offered and time allowed
for consideration. Information sheets and consent forms
will be available in appropriate languages (Luganda or
English in Uganda; Kannada, Dhakani or English in
India); consent discussions will be conducted in the ap-
propriate language and a translator will be used if neces-
sary. Additionally, for any qualitative data collection
(interviews/focus groups), verbal consent will be ob-
tained at the outset.
Intervention
The film-based intervention evaluated in this trial was
developed in conjunction with our partner, Medical Aid
Films (https://www.medicalaidfilms.org/). Medical Aid
Films are a UK-based charity focused on the use of in-
novative media to improve maternal and child health.
They have a significant track record of producing high-
quality films to support the training of health workers
and community-focused behaviour change in LMICs.
Working through an iterative co-production process, we
developed a package of three interconnected educa-
tional/behavioural interventions aimed at (a) improving
knowledge of GDM guidelines and skills among health
providers involved in GDM management, (b) raising
awareness of GDM and the importance of screening
among pregnant women and their family members, and
(c) improving confidence and skills in self-management
for women diagnosed with GDM.
Development phase and theoretical background
The comprehensive intervention development phase in-
cluded a desktop review, followed by a programme of
focus group discussion and interviews with health pro-
fessionals and pregnant women (with and without
GDM) to understand the level of existing knowledge re-
garding GDM, skills, empowerment, resources, cultural
beliefs, and aspirations [25]. Qualitative data were ana-
lysed using descriptive and interpretive phenomenology
approaches. Subsequently, formative research workshops
were held with key stakeholders in order to identify and
review key messages. Drawing on the Health Belief
Model (addressing barriers and emphasising perceived
health benefits), film scripts were drafted and reviewed
by a technical review committee. Filming on location
was undertaken in January (India), February (Uganda)
and September (India) 2020. Local women with experi-
ence of GDM were featured in the films, sharing their
experiences of GDM. Alongside these narrative ele-
ments, we included excerpts from interviews with health
care providers to reinforce key messages. Film content
was piloted at rough-cut and subsequent editing stages
with a small stakeholder group, before being finalised for
implementation and evaluation in February 2021.
Intervention format
The format of the intervention is presented in Table 1.
Films were produced in local languages (Lugunda for
the Ugandan films; Dhakani and Kannada for the Indian
films) with accompanying subtitles; English-language
versions were also produced using a local-accented
English-speaking voiceover artist. The duration of each
of the films is between four and 10 minutes. Although
the content of the films is broadly similar across both
countries, the material has been adapted to reflect the
cultural and clinical context. For example, dietary advice
for pregnant women with GDM refers to popular and
locally available food types. The Indian health profes-
sional films are aligned to national GDM guidelines, em-
phasizing universal GDM screening and home glucose
monitoring for women with GDM. The Uganda versions
reflect the more resource-limited setting, encouraging
GDM screening and deferring to local guidelines regard-
ing GDM management.
Intervention delivery
The intervention has been designed with an emphasis
on sustainability and scalability. In intervention arm fa-
cilities, films will be made available for viewing by doc-
tors and nurses at regular professional meetings. Films
for women and their families will be continuously
screened in waiting areas of antenatal clinics (awareness-
raising film) and during group education sessions for
women diagnosed with GDM (films supporting GDM
self-management). Where intervention settings do not
have existing video/projection facilities, small low-cost
projectors will be made available. Films for women will
additionally be made available for viewing on mobile de-
vices. Health facilities allocated to the control arm will
follow usual care practices.
Outcomes
The trial has two primary outcomes: (1) the proportion
of women diagnosed with GDM by 32 weeks (self-re-
ported) and (2) glycaemic control at ~34 weeks in
women diagnosed with GDM (measured via fasting
blood sugar and HbA1C). While both fasting blood
sugar and HbA1C have some limitations as measures of
glycaemic control in GDM patients, they offer the most
pragmatic solution [26], particularly as glucose self-
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monitoring is not routinely available in all study settings
so would itself constitute an intervention. We anticipate
that any measurement error is likely be randomly dis-
tributed across the two trial arms.
The secondary outcome for the trial is a self-reported
composite outcome consisting of individual indicators
occurring during the perinatal and neonatal period
which are associated with GDM: caesarean delivery,
perinatal or neonatal death, or infant hospitalisation
within 4 weeks of delivery. The use of such a composite
variable is consistent with the approach taken in other
GDM trials [27–29].
While two of the three study outcomes are self-
reported, we hypothesise that these are unlikely to be
misreported due to the nature of the outcomes and the
contemporaneous nature of data collection. We will val-
idate a sample of self-reported outcomes against hospital
records where possible.
Data collection
Data will be collected from all participating women at
three time points: baseline (after informed consent), 32
weeks of pregnancy and approximately 6 weeks after
birth (Fig. 2). A description of the quantitative data to be
collected at each time point is presented in Table 2. We
will require a minimum 1-week interval between base-
line and the first follow-up data collection. Baseline data
will be collected via a face-to-face interview conducted
in the antenatal care setting. Data collection at 32 weeks
and postnatally will be via the telephone, or home visit if
a telephone interview is not possible. The postnatal
follow-up will be timed for approximately 6 weeks after
the expected date of delivery, as final delivery dates will
not be known by the fieldworkers.
A fourth data collection point at ~34 weeks will be
for women who report a GDM diagnosis at the 32-
week telephone interview. These women (approxi-
mately 750 women in each country) will be invited
to attend a clinic visit at ~34 weeks where fasting
blood samples will be collected and tested for fasting
blood glucose and HbA1c in order to assess co-
primary outcome 1 (glycaemic control in women
with GDM).
Data management
Questionnaire data will be collected by fieldworkers
and entered contemporaneously to a secure custom-
designed app with in-built range and consistency
checks. The app is designed with SSL encryption with
SHA2, employs a role-based authentication system
and follows the industry’s best practices for in-system
security. It includes regular automated backup rou-
tines coupled with manually created periodic backup
and point-in-time restoration. Data will be uploaded
in real time to a secure password-protected cloud-
based server, accessed only by authorised study staff.
Fully anonymised data will be transferred for analysis
using a secure encrypted data transfer service to in-
vestigators. Interview/focus group recordings will be
transferred to a secure local server at the Uganda or
India study coordinating centre. All staff involved in
the study will be trained in the study procedures and
good clinical practice.
Fig. 2 Study flow chart
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Data analysis
Available outcome data will be analysed, on an
intention-to-treat basis, in mixed effects models, using a
random effect term to account for clustering at the level
of health facilities. We will consider adjustments for any
baseline imbalances in covariates, and multiple imputa-
tions for missing data, if appropriate. For the co-primary
outcome of glycaemic control, we recognise that the par-
ticipants who are diagnosed with GDM in the two trial
arms may not be comparable. We will consider the use
of propensity score matching to take account of this
non-randomised comparison, if appropriate. Effects of
variation in exposure to the intervention and other rele-
vant effect modifiers will be explored. Qualitative data
will be transcribed and analysed using descriptive and
interpretive phenomenology approaches. A social realist
theoretical framework and thematic analysis will be used
to reveal individual reactions in areas such as emotional
engagement with content, acceptance of messaging, be-
havioural cues, and empathy and support.
Process evaluation
A process evaluation will accompany the trial, drawing
on the MRC framework to assess intervention delivery
(fidelity, dose, reach). The process evaluation will help to
clarify causal mechanisms, both those originally
hypothesised (Fig. 1), and to identify unanticipated
mechanisms. In a complex intervention of this kind, a
process evaluation can help to explore the relationship
between specific intervention components (each of the
three film packages) and our trial outcomes. A range of
quantitative and qualitative data will contribute to the
process evaluation. Quantitative data will include ran-
dom surveys of intervention sites assessing whether films
are being shown as intended, and questionnaire data to
measure whether women receiving care at intervention
facilities recall viewing the study films. We will utilise
ethnographic methods (direct observations including
audio recordings of intervention delivery) and as well as
structured interviews with doctors and nurses, pregnant
women and their family members. We will use purposive
sampling to recruit samples, provisionally planning for
5–15 ethnographic observations, and ~10–20 semi-
structured interviews in each country. Quantitative data
will be collected throughout the duration of the trial,
and qualitative data collection will commence at 6
months.
Power and sample size
Our pilot data suggests that we will be able to recruit
~10,000 pregnant women in each country during the 1-
year recruitment period (~1 delivery/day/unit), of which
~10% (n=500) in intervention arm and ~5% (n=250) in
the control arm are expected to be diagnosed with GDM
(these figures may be lower in Uganda where screening
prevalence is thought to be lower). Our estimated sam-
ple size requirements, based on preliminary data from
Bengaluru and supplemented from literature, for 80%
power at 5% significance level, and accounting for an in-
dicative clustering of 0.01 for all outcomes, are 1218
pregnant women for GDM detection (5% vs 10%), 180
women with GDM for glycaemic control (fasting glucose
difference of 0.3 mmol/L, for an SD of 0.9 mmol/L) [30]
and 5935 women for our composite measure of adverse
perinatal and neonatal outcome (30% vs 35%) [27].
These figures are considerably lower than our planned
sample size.
Ethical considerations and confidentiality
This study will be conducted according to the inter-
national standards of Good Clinical Practice (Inter-
national Conference on Harmonization guidelines),
Declaration of Helsinki, and International Ethical Guide-
lines for Biomedical Research Involving Human Subjects,
Table 2 Schedule of data collection







Tobacco and alcohol use
Physical activity (IPAQ-SF)
Dietary behaviour
32 weeks of pregnancy Quantitative Fieldworker-administered
questionnaire (telephone)
GDM screening
GDM diagnosisPregnancy complicationsKnowledge of GDM
Physical activity (IPAQ-SF)
Dietary behaviour
Intervention recall (intervention arm only)
34 weeks of pregnancy
(women with GDM only)
Biological sample Clinic visit Fasting Blood Sugar (FBS) and HbA1C
~6 weeks after birth Quantitative Fieldworker-administered
questionnaire (telephone)
Perinatal and neonatal outcome
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applicable national government regulations, and institu-
tional research policies and procedures. All investigators
have received Good Clinical Practice training. Ethical ap-
proval has been obtained from the Uganda Virus Re-
search Institute Research and Ethics Committee and the
Uganda National Council of Science and Technology,
The London School of Hygiene and Tropical Medicine’s
Ethics Committee, and from the Indian Institute of Pub-
lic Health, Institutional Ethics Committee, Bengaluru.
There may be minor discomfort from the taking of
blood samples from women diagnosed with GDM; the
patient information leaflet will warn women of this pos-
sibility. There is a possibility that the results of blood
tests (fasting blood glucose) may necessitate additional
clinical treatment/management. In this situation, the
study team will communicate the test results to the
usual healthcare provider. We do not anticipate any risks
of the intervention itself.
We will anonymize all data, replacing identifiable in-
formation with study-specific identifiers at the earliest
opportunity. Consent forms will be stored in a secure,
locked location and access limited to the local PI and
core project staff. Participants will be identified only by
means of study numbers specific to each participant, and
study databases will be password-protected. Upon re-
quest, participant records will be made available to the
study sponsor.
For the qualitative data, when transcriptions are made,
or accounts written up, the name of the respondent will
be replaced by a participant number. All other names of
individuals which may be mentioned by the participant
will be replaced by initials.
Trial governance and monitoring
A Trial Management Group (TMG) has been formed,
consisting of the Chief Investigator, local Principal In-
vestigators, local study coordinators and trial administra-
tors. The TMG holds remote monthly meetings to
oversee the day-to-day running of the trial. The TMG
will be responsible for regular auditing of trial conduct
and for communicating important protocol modifica-
tions to the wider project team and will also formulate
key policies and working groups. A Trial Steering Com-
mittee (TSC) has been convened to provide overall
supervision of both trials, and will meet remotely at
regular intervals determined by need, at a minimum of
once a year. The TSC is chaired by an independent
member and includes experts in the field of maternal
medicine, health psychology and clinical trials. We do
not anticipate any adverse events or unintended effects
of this educational/behavioural intervention, nor do we
envisage the need for any specific post-trial care as a re-
sult of trial participation. A Data and Safety Monitoring
Board (DSMB) at the Indian Institute of Public Health
Bengaluru has responsibility for regular monitoring of
the trial in India. In Uganda, a Data Monitoring Com-
mittee (DMC) has been convened. Both the India DSMB
and Uganda DMC are chaired by independent members
and meet as needed, at a minimum of once a year. Char-
ters and Terms of Reference for the TSC, DSMB and
DMC are available on request. The study sponsor is the
London School of Hygiene and Tropical Medicine.
Dissemination plans
We will publish results arising from the trial including
qualitative work as well as the primary trial analyses, in
established peer-reviewed journals complying with
CONSORT and other relevant guidance. We will also
disseminate the results at international conferences and
meetings. All publications and presentations relating to
the study will be authorised by the Trial Management
Group. In the final phase of the study, we will produce a
research summary and policy recommendations, shared
through our study website, newsletter and professional
networks. We will organise dissemination meetings with
national policy-makers (Ministry of Health, Uganda;
Ministry of Health and Family Welfare, India). A lay
summary of our research will be disseminated to stake-
holders via social media, local networks and participat-
ing health facilities.
Discussion
This trial will evaluate whether an educational/behav-
ioural intervention delivered through a package of cul-
turally tailored films can provide scalable improvements
in the timely detection and management of GDM.
Findings from this project will contribute to scientific
evidence underpinning the use of films in cost-
effectively scaling up behavioural interventions in LMIC
settings. In controlled trials in HIC settings, films have
shown to be effective in increasing participation in HIV
and prostate cancer screening, improving self-care in
heart failure patients, stroke literacy and treatment ad-
herence [20, 31–33]. Visual information is processed far
more efficiently than text [34], making it an effective
method of communication, especially in low-literacy set-
tings where populations have limited opportunity to de-
velop text-based processing skills. Films are an
exceedingly simple and scalable intervention that re-
quires minimal infrastructure. They can be shown via
low-cost projectors in high-volume settings (such as
waiting rooms) and increasingly can be disseminated for
viewing via mobile devices such as smartphones. Films
can be used to deliver simple and accessible information,
and consistent messages [31], yet also provoke discus-
sion and challenge existing beliefs and stigma to pro-
mote behaviour change. Robust data on the effectiveness
of films in delivering behavioural interventions in LMICs
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is critically needed, as given their scalability, they have
the potential to become a key component of strategies
to support behaviour change in chronic diseases. Add-
itionally, this trial will contribute to evidence on cultur-
ally tailored self-management interventions for long-
term conditions, particularly in LMICs, for which exist-
ing evidence is limited.
Trial status
At the time of submission, health facilities have been re-
cruited and randomised, the film-based intervention
finalised and participant recruitment will commence
shortly. Protocol Version 3.2 (26 November 2020).
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